Opinion|Videos|December 17, 2024
Management of Recurrent C Difficile Infections in the Future
Author(s)Paul Feuerstadt, MD, FACG, AGAF
Key Takeaways
- Vowst restores gut microbiome balance using live biotherapeutic products, differing from traditional antibiotic treatments for C. difficile infections.
- Clinical trials showed Vowst significantly reduces recurrence rates, leading to FDA approval for recurrent C. difficile infection.
Paul Feuerstadt, MD, FACG, AGAF, discusses how the management of recurrent Clostridioides difficile infections is evolving toward more targeted approaches, including microbiome-based therapies like fecal microbiota transplantation, newer antibiotics such as fidaxomicin, and emerging preventive strategies focusing on microbiome restoration and preservation.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do you see the management of recurrent C difficile infections moving forward?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FAQs: FDA Lawsuit Challenges E-Cigarette Enforcement Policy, PMTA Guidance
2
Tec-Dara Closes Survival Gap in High-Risk MM: Rahul Banerjee, MD
3
Cognitive Rehabilitation Improves Functional Outcomes in Long COVID Brain Fog
4
PMOS Linked to 4-Fold Atherosclerotic Heart Disease Risk in 2.5 Million US Women
5